Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

QUANTUM GENOMICS : Dr. Catherine Llorens-Cortes receives the 2021 Emilia Valori Prize from the French Academy of Sciences


Press release

Paris, November 23, 2021

Dr. Catherine Llorens-Cortes receives the 2021 Emilia Valori Prize from the French Academy of Sciences

Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specialising in the development of a new class of drugs which act directly on the brain to treat difficult-to-treat/resistant hypertension and heart failure, is pleased to announce that Dr. Catherine
Llorens-Cortes has received from the French Academy of Sciences the 2021 Emilia Valori Prize, in particular for her research on Aminopeptidase A and firibastat.

This prize awarded annually aims to reward a researcher whose work has made a significant scientific contribution likely to have technological applications in the field of chemical, biological or medical sciences.

"I warmly congratulate Catherine Llorens-Cortes and her teams from INSERM and Collège de France laboratories for this prestigious award, which crowns several decades of research work aimed at fostering the emergence of major therapeutic advances, including the Brain Aminopeptidase A inhibitor platform developed by Quantum Genomics," said Jean-Philippe Milon, CEO of Quantum Genomics.

About Quantum Genomics

Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular drugs, based on the Brain Aminopeptidase A Inhibition (BAPAI) mechanism. It is the only company in the world to pursue this innovative approach directly targeting the brain, founded upon more than twenty years of research work by Paris-Descartes University and the INSERM/CNRS laboratory led by Dr. Catherine Llorens-Cortès at the Collège de France. Quantum Genomics thus aims to develop innovative treatments for complicated or even resistant hypertension (in approximately 30% of patients it is poorly controlled or treatment failure occurs), and heart failure (one in two patients diagnosed dies within five years)

Based in Paris and New York, the company is listed on the Euronext Growth market in Paris (FR0011648971 - ALQGC) and is registered on the US OTCQX market (symbol: QNNTF).

Find out more at www.quantum-genomics.com, or on our Twitter and LinkedIn accounts.

Contacts

Quantum Genomics  
contact@quantum-genomics.com  
Edifice Communication (EUROPE)  
Financial communication and media
quantum-genomics@edifice-communication.com
 
LifeSci (USA)  
Mike Tattory
Media communication
+1 (646) 751-4362 - mtattory@lifescipublicrelations.com
 


This publication embed "🔒 Actusnews SECURITY MASTER".
- SECURITY MASTER Key: yWhyZcmaZ2iUnZybYcuYmpdqaWdhlmGXbmibyGOblJiWaGxllW9iZ5uVZnBjlW5m
- Check this key: https://www.security-master-key.com.



Regulated information:
Inside Information:
- other releases


Full and original press release in PDF: https://www.actusnews.com/news/72090-cp-prix-emilia-valori-clc-en.pdf

Receive by email the next press releases of the company by registering on www.actusnews.com, it's free

Source Actusnews

Quantum Genomics S.A. Stock

€4.19
-2.150%
A loss of -2.150% shows a downward development for Quantum Genomics S.A..
The community is currently still undecided about Quantum Genomics S.A. with 1 Buy predictions and 0 Sell predictions.
Like: 0
Share

Comments